Person › Details

Tim Van Hauwermeiren (Argen-X B.V.)

Van Hauwermeiren, Tim (Argen-X 201101 CEO before Ablynx BusDev Manager before P&G)

	Organisation	Argen-X B.V.
	Today	Argen-X N.V. (Argenx) (Euronext + Nasdaq: ARGX)
	Group	Argen-X (Argenx) (Group)
	Former/major organisation	Ablynx N.V. (Euronext Brussels: ABLX, Nasdaq: ABLX)
	Group	Ablynx (Group)
	Product	SIMPLE Antibody™ discovery platform

Record changed: 2018-12-04

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

More documents for Tim Van Hauwermeiren

[1] Argen-X N.V. (Argenx). (12/3/18). "Press Release: Argenx Enters Exclusive Global Collaboration and License Agreement with Cilag GmbH International, an Affiliate of Janssen, for Cusatuzumab (ARGX-110)". Breda & Ghent....
[2] Argen-X N.V. (Argenx). (12/3/18). "Press Release: Argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia". Breda & Ghent....
[3] Argen-X N.V. (Argenx). (8/22/18). "Press Release: Argenx Announces that AbbVie Has Exercised Its Exclusive Option to License ARGX-115, a Novel Immuno-oncology Antibody". Breda & Ghent....
[4] Argen-X N.V. (Argenx). (8/2/18). "Press Release: Argenx Reports Second Quarter Business Update and Half-year 2018 Financial Results". Breda & Ghent....
[5] Argen-X N.V. (Argenx). (4/12/18). "Press Release: Argenx to Receive Third Preclinical Milestone Payment from Collaboration with Leo Pharma". Breda & Ghent....
[6] Argen-X N.V. (Argenx). (4/9/18). "Press Release: Argenx Appoints Keith Woods as Chief Operating Officer". Breda & Ghent....
[7] Argen-X N.V. (Argenx). (3/22/18). "Press Release: Argenx Announces Expansion of Its Pipeline with Addition of Complement-targeted ARGX-117 for Treatment of Severe Autoimmune Diseases". Breda & Ghent....
[8] Argen-X N.V. (Argenx). (11/13/17). "Press Release: Argenx to Present at Upcoming Investor Conferences". Breda & Ghent....
[9] Argen-X N.V. (Argenx). (6/20/17). "Press Release: Argenx Receives Second Preclinical Milestone Payment in Collaboration with Leo Pharma". Breda & Ghent....
[10] Argen-X N.V. (Argenx). (6/13/17). "Press Release: Argenx to Present at JMP Securities Life Sciences Conference". Breda & Ghent....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]